OncoMatch

OncoMatch/Clinical Trials/NCT05261399

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Is NCT05261399 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for carcinoma.

Phase 3RecruitingAstraZenecaNCT05261399Data as of May 2026

Treatment: Savolitinib · Osimertinib · Pemetrexed · Cisplatin · Carboplatin — Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: EGFR exon 19 deletion

Required: EGFR l858r

Required: EGFR t790m

Required: MET amplification

Required: MET overexpression

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — first- or second-line

Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.

Cannot have received: third-generation EGFR TKI

Exception: osimertinib allowed

Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.

Cannot have received: MET inhibitor (savolitinib)

Prior or current treatment with savolitinib or another MET inhibitors.

Lab requirements

Blood counts

adequate haematological function

Kidney function

adequate renal function

Liver function

adequate liver function

Cardiac function

adequate cardiac function and coagulation parameters

Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · La Jolla, California
  • Research Site · Orange City, Florida
  • Research Site · Orlando, Florida
  • Research Site · Honolulu, Hawaii
  • Research Site · Evergreen Park, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify